Evidence map›Paper›PMID 35211780›Full record

ArticleJournal of neurology2022

Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimer's disease: a series of clinical cases.

Nick Corriveau-Lecavalier, Mary M Machulda, Hugo Botha, Jonathan Graff-Radford, David S Knopman, Val J Lowe, Julie A Fields, Nikki H Stricker, Bradley F Boeve, Clifford R Jack and 2 more

Abstract read
In one paragraph

Article in Journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Failed Performance on the Test of Memory Malingering and Misdiagnosis in Individuals with Early-Onset Dysexecutive Alzheimer's Disease.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nick Corriveau-LecavalierDepartment of Neurology, Mayo Clinic, 200 First Street S.W., Rochester, MN, 55905, USA.
Mary M MachuldaDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, 55905, USA.
Hugo BothaDepartment of Neurology, Mayo Clinic, 200 First Street S.W., Rochester, MN, 55905, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, 200 First Street S.W., Rochester, MN, 55905, USA.
David S KnopmanDepartment of Neurology, Mayo Clinic, 200 First Street S.W., Rochester, MN, 55905, USA.
Val J LoweDepartment of Radiology, Mayo Clinic, Rochester, MN, 55905, USA.
Julie A FieldsDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, 55905, USA.
Nikki H StrickerDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, 55905, USA.
Bradley F BoeveDepartment of Neurology, Mayo Clinic, 200 First Street S.W., Rochester, MN, 55905, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, MN, 55905, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, 200 First Street S.W., Rochester, MN, 55905, USA.
David T JonesDepartment of Neurology, Mayo Clinic, 200 First Street S.W., Rochester, MN, 55905, USA. jones.david@mayo.edu.ORCID http://orcid.org/0000-0002-4807-9833

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI BU, GUOJUN · 1999 to 2018
$36.9M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI Walter K. Kremers · 2019 to 2026
$33.5M
PREDICTING ALZHEIMERS DISEASE WITH MAGNETIC RESONANCER01AG011378 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R. · 1993 to 2017
$12.1M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
Validating the New Criteria for Preclinical Alzheimer's diseaseR01AG041851 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R., KNOPMAN, DAVID S · 2012 to 2021
$6.3M
NIA NIH HHS P30 AG062677NIA NIH HHS P50 AG016574NIA NIH HHS R01 AG011378NIA NIH HHS R01 AG041851NIA NIH HHS U01 AG006786NIH HHS AG011378NIH HHS AG016574NIH HHS AG041851NIH HHS AG06786
6 · The paper itself

Abstract

Diagnostic criteria for a progressive dysexecutive syndrome due to Alzheimer's disease (dAD) were proposed. Clinical observations suggest substantial variability in the clinico-radiological profiles within this syndrome. We report a case series of 6 patients with dAD highlighting this heterogeneity. Average age at diagnosis was 57.3 years, and patients were followed annually with clinical, cognitive, and multimodal imaging assessments for an average of 3.7 years. Cases were divided based into three subtypes based on their pattern of FDG-PET hypometabolism: predominantly left parieto-frontal (ldAD), predominantly right parieto-frontal (rdAD), or predominantly biparietal (bpdAD) (n = 2 for each). Prominent executive dysfunction was evidenced in all patients. ldAD cases showed greater impairment on measures of verbal working memory and verbal fluency compared to other subtypes. rdAD cases showed more severe alterations in measures of visual abilities compared to language-related domains and committed more perseverative errors on a measure of cognitive flexibility. bpdAD cases presented with predominant cognitive flexibility and inhibition impairment with relative sparing of working memory and a slower rate of clinical progression. rdAD and bpdAD patients developed neuropsychiatric symptoms, whereas none of the ldAD patients did. For each subtype, patterns of tau deposition relatively corresponded to the spatial pattern of FDG hypometabolism. dAD cases could be differentiated from two clinical cases of atypical AD variants (language and visual) in terms of clinical, cognitive and neuroimaging profiles, suggesting that dAD subtypes represent clinical entities separable from other variants of the disease. The recognition of distinct dAD phenotypes has clinical relevance for diagnosis, prognosis, and symptom management.

Indexed as

Alzheimer DiseaseBrainFluorodeoxyglucose F18HumansMemory, Short-TermNeuropsychological TestsPhenotypePositron-Emission TomographyFluorodeoxyglucose F18Atypical Alzheimer’s diseaseClinical neurologyDysexecutive syndromeFDG–PETNeuropsychology

Identifiers

PMID35211780
PMCPMC9308626

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.